Junshi Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Junshi bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Junshi Bio Today - Breaking & Trending Today

CSPC's net inches up

Staff reporter CSPC Pharmaceutical s (1093) net profit for the first three quarters of the year inched up 0.6 percent year-on-year to 4.5 bi. ....

Yao Sheng , Junshi Bio , Coherus Biosciences , Drug Administration , Junshi Biotechnology , The Standard , Ection News , Op News , Entral Station ,

Will Junshi Bio's Loss-Making Headaches Ease With Landmark U.S. Drug Approval?

Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s recent approval by the FDA • The… ....

Junshi Bio , Reaking News ,

Will Junshi Bio's Loss-Making Headaches Ease With Landmark U.S. Drug Approval? - BeiGene (NASDAQ:BGNE), Coherus BioSciences (NASDAQ:CHRS)

Key Takeaways: Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s recent approval by the FDA The drug maker’s revenue fell 19% year-on-year in the first nine months of 2023, as its net loss narrowed to 1.41 billion yuan By Molly Wen ....

United States , United Kingdom , South Africa , Hong Kong , Junshi Bio , Coheru Toripalimab , Molly Wen , Shanghai Junshi Biosciences Co , World Health Organization , Revenue Booster , Drug Administration , Shanghai Junshi Biosciences , Chinesea Share , Southeast Asia , Middle East , North Africa , Latin America ,

Drug Maker Junshi Seeks Swiss Cure For Cash Woes - BeiGene (NASDAQ:BGNE), Coherus BioSciences (NASDAQ:CHRS)

Key Takeaways: Junshi Biosciences reported dismal results in the first quarter, with operating income plunging nearly 60% and its net loss expanding by 37% Hopes of a big revenue boost from an oral Covid drug have been dashed, and the company may not recoup its investment in the short term By Molly Wen ....

Hong Kong , United States , Junshi Bio , Junshi Biosciences , Eli Lilly , Molly Wen , Cansino Biologics , Swiss Exchange , Hong Kong Stock Exchange , Coherus Biosciences Inc , China Meheco Group , Shanghai Junshi Biosciences Co , Key Takeaways , Global Depositary Receipts , Guosheng Securities , Rxilient Biotech ,

The future of Chinese tech stocks: Is it time to invest in them again?

The Chinese stock market has seen a difficult two years. Starting with harsh regulatory crackdowns in late 2020, and then followed by strict Covid-19 lockdowns that saw entire cities grind to a standstill, the result was billions of dollars wiped off the books of China’s tech giants and once-promising enterprises. However, things are headed for a change. China is attempting. ....

Hong Kong , Junshi Bio , Jack Ma , Ant Group , Montage Technology , Kingsoft Office Software , Party Of China , China Construction Bank , Semiconductor Manufacturing Intern , Jd Health , Silicon Valley , Communist Party , Golden Dragon China Index , Shares Core , Ping An Insurance , Shares Hang Seng Tech , Share Hang Seng Tech , Semiconductor Manufacturing , Trina Solar , Western Superconducting ,